Akero Therapeutics (AKRO) has hired an investment bank and is exploring a potential sale after being approached by a strategic buyer about a takeover, according to Street Insider, citing a source.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
- Akero Therapeutics price target lowered to $78 from $80 at Citi
- Akero Therapeutics Advances in MASH Treatment Research
- Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
- Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating